ERBB4 and anaplastic large cell lymphoma: Nevertheless, the pharmacologic inhibition of ERBB4 only partially controls ALCL cell growth and disease progression in a preclinical model, indicating the need for combination therapies in relapsed or refractory ERBB4-positive ALCL patients.